Digestion‑resistant maltodextrin effects on colonic transit time and stool weight: a randomized controlled clinical study

Purpose Increased awareness of the importance of dietary fibre has led to increased interest in “functional” fibre components like digestion-resistant maltodextrin (RMD). This randomized, placebo-controlled, double-blind study assessed the effects of RMD in the colonic transit time (CTT) and defecat...

Descripción completa

Detalles Bibliográficos
Autores: Abellán Ruiz, María Salud, Barnuevo Espinosa, María Dolores, Contreras Fernández, Carlos J., Luque Rubia, Antonio J., Sánchez Ayllón, Francisca, Aldeguer García, Miriam, García Santamaría, Carlos, López Román, Francisco Javier
Tipo de recurso: artículo
Fecha de publicación:2016
País:España
Institución:Universidad Católica San Antonio de Murcia (UCAM)
Repositorio:RIUCAM. Repositorio Institucional de la Universidad Católica San Antonio de Murcia
OAI Identifier:oai:repositorio.ucam.edu:10952/10760
Acceso en línea:http://hdl.handle.net/10952/10760
Access Level:acceso abierto
Palabra clave:Colonic transit time
Resistant maltodextrin
Soluble dietary fibre
Stool volume
Intestinal function
Descripción
Sumario:Purpose Increased awareness of the importance of dietary fibre has led to increased interest in “functional” fibre components like digestion-resistant maltodextrin (RMD). This randomized, placebo-controlled, double-blind study assessed the effects of RMD in the colonic transit time (CTT) and defecation characteristics (frequency, stool volume and consistency). Methods Sixty-six healthy adult volunteers (32 men) who did not have a daily defecation habit had a 7-day run-in period before the 21-day intervention period with RMD or placebo. CTT and segmental CTT (SCTT) were assessed by a single abdominal X-ray film taken at the end of both periods after radiopaque marker ingestion. Defecation characteristics and intestinal functions were also assessed, which were self-reported by patients. Intragroup comparisons were evaluated by Student’s paired t test, Bonferroni test and Chi-square test, while time comparisons by analysis of variance (ANOVA) and time-by-treatment interaction by repeated-measures ANOVA. Results Fifty-seven subjects were assessed for CTT (placebo, n = 28; RMD, n = 29). In the RMD group, the total CTT, left SCTT and rectosigmoidal SCTT decreased significantly compared to baseline (p < 0.01 each; −13.3, −4.7, −8.7 h, respectively). Significant differences between groups were observed in total CTT and left SCTT.Significant time-by-treatment interaction was observed in the RMD group for stool volume (p = 0.014), increasing 56 % compared to baseline (p < 0.01), while remained unchanged in the placebo group. Stool consistency was improved only in the RMD group (p < 0.01). No adverse effects related to study products were observed. Conclusions The results show that RMD improved CTT, stool volume, stool consistency and some intestinal functions in a healthy population.